Vyzulta FDA Approval History
FDA Approved: Yes (First approved November 2, 2017)
Brand name: Vyzulta
Generic name: latanoprostene bunod
Dosage form: Ophthalmic Solution
Previous Name: Vesneo
Company: Bausch Health Companies Inc.
Treatment for: Glaucoma, Open Angle, Intraocular Hypertension
Vyzulta (latanoprostene bunod) is a nitric oxide donating prostaglandin receptor agonist for the treatment of patients with open angle glaucoma or ocular hypertension.
Development Timeline for Vyzulta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.